Research that Identifies
Undiscovered Value in the MicroCap Market


Nexeon Medsystems, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Updated Research Report (Dated 06/08/2018)

Symbol: NXNN
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $2.00
Time Horizon: 12 Months
Rating Established: January 9, 2018
Price When Established: $1.01
Most Recent Report: June 8, 2018
Price When Issued: $0.75

What's New

Nexeon Medsystems Reports 2Q18 Results

On August 13, 2018, Nexeon Medsystems reported 2Q18 results for the three-months ended June 30, 2018.

NXNN reported 2Q18 net loss of $700,000 or ($0.37) per share, on revenue of $2.8 million. In the year-ago period the company reported a net loss of $1.4 million or ($0.80) per share on revenue of $1.7 million.

Taglich Brothers estimated 2Q18 revenues of $2.2 million and a net loss of $950,000 or ($0.70) per share.

All per share figures reflect the 1 for 14 reverse stock-split effective on June 25, 2018.

Company Description

Nexeon Medsystems, Inc., headquartered in Dallas, TX, is a global medical device company focused on providing neurostimulation products to improve the quality of life for patients suffering from neurological diseases. NXNN’s Belgian-based Medi-Line subsidiary provides global medical device outsource manufacturing solutions for existing customers and long term supply contracts with Fortune 50 companies.

Company Reports

Updated Research Report (Dated June 8, 2018)

Updated Research Report (Dated May 4, 2018)

Initial Research Report (Dated January 9, 2018)


Please view our current disclosure and disclaimer on our most recent research report.